SABSW · As filed with the SEC
SAB Biotherapeutics cash flow statement, by quarter
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows (Unaudited) · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net income (loss) | — | (18,868,885) | — | — | — | (5,196,773) | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | — | 730,965 | — | — | — | 756,595 | — | — |
| Amortization of finance right-of-use assets | — | 21,705 | — | — | — | 21,706 | — | — |
| Stock-based compensation expense | — | 5,459,911 | — | — | — | 612,951 | — | — |
| Gain on the sale of equipment | — | (2,217) | — | — | — | — | — | — |
| Net realized and unrealized (gain) loss on equity securities | — | 9,587 | — | — | — | (961) | — | — |
| Net realized gain on debt securities | — | (47,089) | — | — | — | — | — | — |
| Changes in fair value of warrant liabilities | — | 482,474 | — | — | — | (5,035,769) | — | — |
| Accretion of discounts on investments | — | 10,075 | — | — | — | (19,489) | — | — |
| Gain in early termination of lease liability | — | (7,042) | — | — | — | — | — | — |
| Changes in operating assets and liabilities | ||||||||
| Accrued interest receivable | — | (608,280) | — | — | — | 33,569 | — | — |
| Prepaid expenses and other current assets | — | (297,263) | — | — | — | (291,075) | — | — |
| Operating lease right-of-use assets and liabilities, net | — | (74,224) | — | — | — | 54,785 | — | — |
| Accounts payable | — | 114,119 | — | — | — | 684,171 | — | — |
| Accrued expense and other current liabilities | — | (1,194,966) | — | — | — | 583,073 | — | — |
| Net cash used in operating activities | — | (14,271,130) | — | — | — | (7,797,217) | — | — |
| Cash flows from investing activities: | ||||||||
| Proceeds from the sale of equipment | — | 2,217 | — | — | — | 500 | — | — |
| Purchases of property, plant and equipment | — | (983,257) | — | — | — | — | — | — |
| Purchases of investments | — | (139,262,781) | — | — | — | (70,905) | — | — |
| Proceeds from sales and maturities of investments | — | 74,596,145 | — | — | — | 4,741,508 | — | — |
| Net cash (used in) provided by investing activities | — | (65,647,676) | — | — | — | 4,671,103 | — | — |
| Cash flows from financing activities: | ||||||||
| Principal payments of notes payable | — | — | — | — | — | (137,295) | — | — |
| Proceeds from the March 2026 Public Offering, net of issuance costs | — | 79,636,964 | — | — | — | — | — | — |
| Proceeds from the March 2026 Public Offering and Underwriters' Option, net of issuance costs | — | 7,238,000 | — | — | — | — | — | — |
| Proceeds from exercised Enrollment Date and Release Date Warrants | — | 2,975,000 | — | — | — | — | — | — |
| Principal payments on finance leases | — | (37,388) | — | — | — | (34,618) | — | — |
| Proceeds from exercise of stock options | — | 113,116 | — | — | — | — | — | — |
| Tax payments for share settlement of restricted stock units | — | (4,571) | — | — | — | (2,072) | — | — |
| Net cash provided by (used in) financing activities | — | 89,921,121 | — | — | — | (173,985) | — | — |
| Effect of exchange rate changes on cash and cash equivalents | — | 14,729 | — | — | — | 42,500 | — | — |
| Net decrease in cash and cash equivalents | — | 10,017,044 | — | — | — | (3,257,599) | — | — |
| Cash and cash equivalents | ||||||||
| Beginning of period | 20,519,724 | 10,502,680 | 29,424,708 | 3,691,000 | 5,640,367 | 8,897,966 | 9,171,175 | 17,242,442 |
| End of period | 8,267,000 | 20,519,724 | 10,502,680 | 29,424,708 | 3,692,217 | 5,640,367 | 8,897,966 | 9,171,175 |
| Supplemental cash flow information: | ||||||||
| Cash paid for interest | — | 62,986 | — | — | — | 70,011 | — | — |
| Supplemental information on non-cash investing and finance activities: | ||||||||
| Right-of-use asset written off due to early termination of lease | — | 368,425 | — | — | — | — | — | — |
| Operating lease liability written off due to early termination of lease | — | 280,415 | — | — | — | — | — | — |
| Right-of-use assets obtained in exchange for operating lease liabilities | — | 775,143 | — | — | — | 2,422,191 | — | — |
| March 2026 Public Offering Issuance Costs included in accrued expenses | — | 386,335 | — | — | — | — | — | — |
| Purchases of equpment included in accounts payable | — | 255,376 | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.